Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.8800 (1.31%) ($3.7600 - $3.8800) on Tue. Jan. 25, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.1% (three month average) | RSI | 13 | Latest Price | $3.8800(1.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.7% a day on average for past five trading days. | Weekly Trend | AUTL declines -9.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(64%) IBB(59%) IBUY(56%) ARKG(52%) ARKK(52%) | Factors Impacting AUTL price | AUTL will decline at least -2.55% in a week (0% probabilities). VIXM(-40%) VXX(-33%) TIP(-25%) TLT(-23%) SHY(-22%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.55% (StdDev 5.1%) | Hourly BBV | 0.4 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-15.57(-501.29%) | Resistance Level | $4.61 | 5 Day Moving Average | $3.98(-2.51%) | 10 Day Moving Average | $4.21(-7.84%) | 20 Day Moving Average | $4.61(-15.84%) | To recent high | -44.9% | To recent low | 1.3% | Market Cap | $203m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |